{"id":{"repo_id":"csusb","oai_identifier":"oai:scholarworks.lib.csusb.edu:etd-2053"},"canonical_url":"https://search.ndltd.org/etd/csusb/oai:scholarworks.lib.csusb.edu:etd-2053","repository":{"repo_id":"csusb","name":"CSUniversity San Bernardino","base_url":"https://scholarworks.lib.csusb.edu/do/oai/"},"display":{"title":"EARLY-LIFE METHYLPHENIDATE DECREASES SOCIAL ANXIETY IN ADULT FEMALE RATS WITHOUT CENTRAL DOPAMINE DEFICIENCY","abstract":"Methylphenidate (MPH) is the most commonly-prescribed medication for treating ADHD. Despite high prescription rates among kindergarten-aged children, MPH was not approved for use in children younger than nine, and research into its long-term consequences is lacking. Here, we examined the effects of early-life MPH exposure on anxiety-like behaviors in adulthood in normal rats and rats with dysfunctional central dopamine. On postnatal day (PD) 3, male and female rat pups were injected intracisternally with 6-OHDA or vehicle to generate normal and dopamine-deficient groups. In an initial pair of experiments, 6-OHDA (50, 100 and 150 µg/10µL infusion) was assessed for its ability to induce an ADHD-like phenotype. Subsequently, rats were lesioned with 6-OHDA (100 µg/infusion) or vehicle on PD3 and given MPH (0, 0.5, 2 or 5 mg/kg, i.p.) once daily for 10 days, starting on PD11. On PD60, anxiety-like behavior was assessed with light/dark box or social interaction tests. On PD65, all rats were tested on the elevated plus maze (EPM). Rats with neonatal 6-OHDA lesions exhibited anxiety-like behavior in the light/dark box test and on the EPM. However, there was a complex interaction between sex, lesion, and drug dose in the social interaction test. Pretreatment with 2 mg/kg MPH increased investigatory behaviors in non-lesioned females and decreased investigatory behaviors in lesioned females, suggesting that the long-term effects of early-life MPH in females depend on normal dopamine levels. Together, these experiments support the efficacy of preclinical ADHD models and diverse measures of anxiety-like behaviors when studying the effects of early-life MPH exposure.","abstract_html":"Methylphenidate (MPH) is the most commonly-prescribed medication for treating ADHD. Despite high prescription rates among kindergarten-aged children, MPH was not approved for use in children younger than nine, and research into its long-term consequences is lacking. Here, we examined the effects of early-life MPH exposure on anxiety-like behaviors in adulthood in normal rats and rats with dysfunctional central dopamine. On postnatal day (PD) 3, male and female rat pups were injected intracisternally with 6-OHDA or vehicle to generate normal and dopamine-deficient groups. In an initial pair of experiments, 6-OHDA (50, 100 and 150 µg/10µL infusion) was assessed for its ability to induce an ADHD-like phenotype. Subsequently, rats were lesioned with 6-OHDA (100 µg/infusion) or vehicle on PD3 and given MPH (0, 0.5, 2 or 5 mg/kg, i.p.) once daily for 10 days, starting on PD11. On PD60, anxiety-like behavior was assessed with light/dark box or social interaction tests. On PD65, all rats were tested on the elevated plus maze (EPM). Rats with neonatal 6-OHDA lesions exhibited anxiety-like behavior in the light/dark box test and on the EPM. However, there was a complex interaction between sex, lesion, and drug dose in the social interaction test. Pretreatment with 2 mg/kg MPH increased investigatory behaviors in non-lesioned females and decreased investigatory behaviors in lesioned females, suggesting that the long-term effects of early-life MPH in females depend on normal dopamine levels. Together, these experiments support the efficacy of preclinical ADHD models and diverse measures of anxiety-like behaviors when studying the effects of early-life MPH exposure.","abstract_has_math":false,"creators":["Kaplan, Graham James"],"institution":null,"degree_name":"Master of Arts in General Experimental Psychology","degree_level":"Restricted Thesis: Campus only access","degree_discipline":"Psychology","degree_department":null,"school":null,"contributors":["Crawford, Cynthia"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:07:19Z","subjects":["methylphenidate; anxiety; ADHD; 6-OHDA; dopamine; ontogeny","Biological Psychology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://scholarworks.lib.csusb.edu/etd/951","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://scholarworks.lib.csusb.edu/etd/951","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://scholarworks.lib.csusb.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Ascholarworks.lib.csusb.edu%3Aetd-2053","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Crawford, Cynthia"]},{"key":"dc:creator","label":"Author","values":["Kaplan, Graham James"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2019-10-03T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2019-12-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Psychology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Restricted Thesis: Campus only access"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Arts in General Experimental Psychology"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["methylphenidate; anxiety; ADHD; 6-OHDA; dopamine; ontogeny","Biological Psychology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://scholarworks.lib.csusb.edu/etd/951"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Methylphenidate (MPH) is the most commonly-prescribed medication for treating ADHD. Despite high prescription rates among kindergarten-aged children, MPH was not approved for use in children younger than nine, and research into its long-term consequences is lacking. Here, we examined the effects of early-life MPH exposure on anxiety-like behaviors in adulthood in normal rats and rats with dysfunctional central dopamine. On postnatal day (PD) 3, male and female rat pups were injected intracisternally with 6-OHDA or vehicle to generate normal and dopamine-deficient groups. In an initial pair of experiments, 6-OHDA (50, 100 and 150 µg/10µL infusion) was assessed for its ability to induce an ADHD-like phenotype. Subsequently, rats were lesioned with 6-OHDA (100 µg/infusion) or vehicle on PD3 and given MPH (0, 0.5, 2 or 5 mg/kg, i.p.) once daily for 10 days, starting on PD11. On PD60, anxiety-like behavior was assessed with light/dark box or social interaction tests. On PD65, all rats were tested on the elevated plus maze (EPM). Rats with neonatal 6-OHDA lesions exhibited anxiety-like behavior in the light/dark box test and on the EPM. However, there was a complex interaction between sex, lesion, and drug dose in the social interaction test. Pretreatment with 2 mg/kg MPH increased investigatory behaviors in non-lesioned females and decreased investigatory behaviors in lesioned females, suggesting that the long-term effects of early-life MPH in females depend on normal dopamine levels. Together, these experiments support the efficacy of preclinical ADHD models and diverse measures of anxiety-like behaviors when studying the effects of early-life MPH exposure."]},{"key":"dc:title","label":"Title","values":["EARLY-LIFE METHYLPHENIDATE DECREASES SOCIAL ANXIETY IN ADULT FEMALE RATS WITHOUT CENTRAL DOPAMINE DEFICIENCY"]}]}],"canonical_facts":{"dc:contributor":["Crawford, Cynthia"],"dc:creator":["Kaplan, Graham James"],"dc:date.available":["2019-10-03T07:00:00Z"],"dc:date.created":["2019-12-01T08:00:00Z"],"dc:description.abstract":["Methylphenidate (MPH) is the most commonly-prescribed medication for treating ADHD. Despite high prescription rates among kindergarten-aged children, MPH was not approved for use in children younger than nine, and research into its long-term consequences is lacking. Here, we examined the effects of early-life MPH exposure on anxiety-like behaviors in adulthood in normal rats and rats with dysfunctional central dopamine. On postnatal day (PD) 3, male and female rat pups were injected intracisternally with 6-OHDA or vehicle to generate normal and dopamine-deficient groups. In an initial pair of experiments, 6-OHDA (50, 100 and 150 µg/10µL infusion) was assessed for its ability to induce an ADHD-like phenotype. Subsequently, rats were lesioned with 6-OHDA (100 µg/infusion) or vehicle on PD3 and given MPH (0, 0.5, 2 or 5 mg/kg, i.p.) once daily for 10 days, starting on PD11. On PD60, anxiety-like behavior was assessed with light/dark box or social interaction tests. On PD65, all rats were tested on the elevated plus maze (EPM). Rats with neonatal 6-OHDA lesions exhibited anxiety-like behavior in the light/dark box test and on the EPM. However, there was a complex interaction between sex, lesion, and drug dose in the social interaction test. Pretreatment with 2 mg/kg MPH increased investigatory behaviors in non-lesioned females and decreased investigatory behaviors in lesioned females, suggesting that the long-term effects of early-life MPH in females depend on normal dopamine levels. Together, these experiments support the efficacy of preclinical ADHD models and diverse measures of anxiety-like behaviors when studying the effects of early-life MPH exposure."],"dc:identifier":["https://scholarworks.lib.csusb.edu/etd/951"],"dc:subject":["methylphenidate; anxiety; ADHD; 6-OHDA; dopamine; ontogeny","Biological Psychology"],"dc:title":["EARLY-LIFE METHYLPHENIDATE DECREASES SOCIAL ANXIETY IN ADULT FEMALE RATS WITHOUT CENTRAL DOPAMINE DEFICIENCY"],"thesis:degree_discipline":["Psychology"],"thesis:degree_level":["Restricted Thesis: Campus only access"],"thesis:degree_name":["Master of Arts in General Experimental Psychology"]},"updated_at":"2026-11-19T08:07:19Z"}